Oramed Pharmaceuticals Stock Price Prediction
| ORMP Stock | USD 2.34 0.03 1.30% |
Oversold Vs Overbought
46
Oversold | Overbought |
EPS Estimate Current Year 0.24 | EPS Estimate Next Year (0.08) | Wall Street Target Price 3.25 | EPS Estimate Current Quarter 0.01 | Quarterly Revenue Growth (1.00) |
Using Oramed Pharmaceuticals hype-based prediction, you can estimate the value of Oramed Pharmaceuticals from the perspective of Oramed Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Oramed Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Oramed because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Oramed Pharmaceuticals after-hype prediction price | USD 2.34 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Oramed |
Oramed Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Oramed Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Oramed Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Oramed Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Oramed Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Oramed Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Oramed Pharmaceuticals' historical news coverage. Oramed Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.12 and 4.68, respectively. We have considered Oramed Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Oramed Pharmaceuticals is relatively risky at this time. Analysis and calculation of next after-hype price of Oramed Pharmaceuticals is based on 3 months time horizon.
Oramed Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Oramed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oramed Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Oramed Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.06 | 2.34 | 0.00 | 0.00 | 5 Events / Month | 9 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.34 | 2.34 | 0.00 |
|
Oramed Pharmaceuticals Hype Timeline
Oramed Pharmaceuticals is now traded for 2.34. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Oramed is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is expected to be very small, whereas the daily expected return is now at -0.06%. %. The volatility of related hype on Oramed Pharmaceuticals is about 4254.55%, with the expected price after the next announcement by competition of 2.34. About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oramed Pharmaceuticals had not issued any dividends in recent years. The entity had 1:12 split on the 23rd of January 2013. Given the investment horizon of 90 days the next expected press release will be in about 5 days. Check out Oramed Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Oramed Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Oramed Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Oramed Pharmaceuticals' future price movements. Getting to know how Oramed Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Oramed Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CAPR | Capricor Therapeutics | (0.08) | 11 per month | 4.10 | 0.23 | 18.22 | (7.37) | 69.31 | |
| AKTX | Akari Therapeutics PLC | 0.22 | 5 per month | 0.00 | (0.24) | 4.84 | (12.30) | 47.27 | |
| SLNO | Soleno Therapeutics | 0.67 | 10 per month | 2.49 | 0.06 | 6.31 | (4.12) | 13.33 | |
| BPTH | Bio Path Holdings | 0.05 | 9 per month | 0.00 | (0.09) | 6.67 | (8.08) | 51.22 | |
| MBRX | Moleculin Biotech | (0.20) | 9 per month | 4.27 | 0.04 | 9.75 | (7.01) | 35.41 | |
| CRNX | Crinetics Pharmaceuticals | 1.32 | 9 per month | 2.43 | (0.01) | 3.67 | (3.45) | 16.75 | |
| ASMB | Assembly Biosciences | (0.72) | 8 per month | 4.46 | 0.01 | 8.49 | (5.34) | 24.80 | |
| TIL | Instil Bio | (1.77) | 9 per month | 6.84 | 0.12 | 20.63 | (10.89) | 105.83 | |
| CTMX | CytomX Therapeutics | (0.01) | 9 per month | 0.00 | (0.15) | 5.00 | (5.22) | 20.61 | |
| ACHL | Achilles Therapeutics PLC | (0.03) | 4 per month | 1.53 | 0.11 | 3.06 | (2.88) | 38.16 |
Oramed Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Oramed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Oramed using various technical indicators. When you analyze Oramed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Oramed Pharmaceuticals Predictive Indicators
The successful prediction of Oramed Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Oramed Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Oramed Pharmaceuticals based on analysis of Oramed Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Oramed Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Oramed Pharmaceuticals's related companies. | 2023 | 2024 (projected) | Graham Number | 8.29 | 8.7 | Receivables Turnover | 1.88 | 0.98 |
Story Coverage note for Oramed Pharmaceuticals
The number of cover stories for Oramed Pharmaceuticals depends on current market conditions and Oramed Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Oramed Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Oramed Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Oramed Pharmaceuticals Short Properties
Oramed Pharmaceuticals' future price predictability will typically decrease when Oramed Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Oramed Pharmaceuticals often depends not only on the future outlook of the potential Oramed Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oramed Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.3 M |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.